signing contract



Ligand Pharmaceuticals will acquire core assets, partnered programs and ion channel technologies from Icagen

Ligand Pharmaceuticals, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, announced that it has agreed to acquire the core assets of Icagen’s North Carolina operations.
The acquired assets include Icagen’s proprietary ion channel platforms, partnered programs on neurological diseases and cystic fibrosis, as well as internal programs on neurodegenerative diseases, pain, diabetes, and other disorders.
The transaction is projected to close in April 2020.

Read more about Ligand Pharmaceuticals here.

Image by Free-Photos from Pixabay